Cefazolin vs. antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis
Clinical Microbiology and Infection · 2025-08 · 31 (8) · 1272-1282
DOI: 10.1016/j.cmi.2025.04.045 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Microbiology and Infection, 2025-08. Verfasst von Connor Prosty und 14 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, McGill University, Montréal, Québec, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montr…. Hauptthemen laut MEDLINE: Cefazolin, Staphylococcal Infections, Anti-Bacterial Agents, Bacteremia. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: There is debate on whether cefazolin or antistaphylococcal penicillins should be the first-line treatment for methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia. Ongoing trials are investigating whether cefazolin is non-inferior to (flu)cloxacillin, but it remains uncertain whether these findings apply to other antistaphylococcal penicillins. OBJECTIVES: We conducted a systematic review and meta-analysis comparing cefazolin with each of the individual antistaphylococcal penicillins for MSSA bacteraemia. METHODS: Data sources: We updated a 2019 systematic review but specifically focused on evaluating outcomes by individual antistaphylococcal penicillins. STUDY ELIGIBILITY CRITERIA: Study eligibility criteria include comparative observational studies. PARTICIPANTS: Participants include patients with MSSA bacteraemia. INTERVENTIONS: Interventions include cefazolin vs. the antistaphylococcal penicillins. ASSESSMENT OF RISK OF BIAS: Assessment of risk of bias involved the risk of bias in non-randomized studies of interventions tool. METHODS OF DATA SYNTHESIS: The primary outcome was 30-day all-cause mortality and we assessed for non-inferiority of cefazolin using a pre-specified non-inferiority margin of a pooled OR
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, McGill University, Montréal, Québec, Canada; Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Québec, Canada. Electronic address: connor.prosty@mail.mcgill.ca.
- Faculty of Medicine, McGill University, Montréal, Québec, Canada.
- Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Québec, Canada; Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Québec, Montréal, Canada;…
- Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
- School of Medicine and Public Health, University of Newcastle, Newcastle, Australia; Department of Immunology and Infectious Diseases, John Hunter Hospital, Newcastle, Australia; Global and Tropical Health Division, Men…
- Department of Pharmacy, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Zitieren
APA
Prosty, C., Noutsios, D., Lee, T. C., Daneman, N., Davis, J. S., Jager, N. G. L., Ghanem-Zoubi, N., Goodman, A. L., Kaasch, A. J., Kouijzer, I., McMullan, B. J., McDonald, E. G., Tong, S. Y. C., Ong, S. W. X., & Staphylococcus aureus Network Adaptive Platform MSSA/PSSA domain specific working group (2025). Cefazolin vs. antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis. Clinical Microbiology and Infection, 31(8), 1272-1282. https://doi.org/10.1016/j.cmi.2025.04.045
Vancouver
Prosty C, Noutsios D, Lee TC, Daneman N, Davis JS, Jager NGL, et al. Cefazolin vs. antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis. Clinical Microbiology and Infection. 2025;31(8):1272-1282. doi:10.1016/j.cmi.2025.04.045
BibTeX
@article{Prosty2025,
author = {Prosty, Connor and Noutsios, Dean and Lee, Todd C and Daneman, Nick and Davis, Joshua S and Jager, Nynke G L and Ghanem-Zoubi, Nesrin and Goodman, Anna L and Kaasch, Achim J and Kouijzer, Ilse and McMullan, Brendan J and McDonald, Emily G and Tong, Steven Y C and Ong, Sean W X and Staphylococcus aureus Network Adaptive Platform MSSA/PSSA domain specific working group, Staphylococcus aureus Network Adaptive Platform MSSA/PSSA domain specific working group},
title = {Cefazolin vs. antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis},
journal = {Clinical Microbiology and Infection},
year = {2025},
volume = {31},
number = {8},
pages = {1272--1282},
doi = {10.1016/j.cmi.2025.04.045}
}
EUVIMED